New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
10:45 EDTSRPTLeerink still cautious on FDA approving eteplirsen with existing data
Leerink says it continues to have reservations that the FDA will approve Sarepta's eteplirsen on its existing data set. The firm thinks today's news supports its belief that the FDA is "kicking the can down the road" on an eteplirsen decision until it obtains more analyzed data. Leerink reiterates a Market Perform rating on Sarepta with a $31 price target.
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
09:01 EDTSRPTSarepta enters into partnership with Flagship Biosciences
Sarepta Therapeutics and Flagship Biosciences announced a multi-year, multi-product partnership for the development of automated quantitative endpoint measurements in muscular dystrophy to support the advancement of Sarepta’s Duchenne muscular dystrophy drug pipeline, including its lead candidate, eteplirsen. This newly established collaboration with Flagship demonstrates Sarepta’s commitment to enhancing the objective measurement of dystrophin in tissue samples for its growing pipeline of RNA-based therapeutics to treat DMD.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use